SEQUENCE LISTING

```
<110> Huang, Ziwei
```

<120> A novel peptide antagonist of CXCR4 derived from the N-terminus of viral chemokine vMIP-II

<130> CXCR4 Peptide Antagonist Prov.

<140>

<141>

<160> 33

<170> PatentIn Ver. 2.1

<21.0> 1

<211> 71

<212> PRT

<213> Herpesvirus

<400> 1

Leu Gly Ala Ser Trp His Arg Pro Asp Lys Cys Cys Leu Gly Tyr Gln $1 \hspace{1.5cm} 5 \hspace{1.5cm} 10 \hspace{1.5cm} 15$

Lys Arg Pro Leu Pro Gln Val Leu Leu Ser Ser Trp Tyr Pro Thr Ser 20 25 30

Gln Leu Cys Ser Lys Pro Gly Val Ile Phe Leu Thr Lys Arg Gly Arg 35 40 45

Gln Val Cys Ala Asp Lys Ser Lys Asp Trp Val Lys Lys Leu Met Gln 50 55

Gln Leu Pro Val Thr Ala Arg

<210> 2

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: vMIP-II derived peptide

<400> 2

```
Leu Gly Ala Ser Trp His Arg Pro Asp Lys Cys Cys Leu Gly Tyr Gln
       1
                       5
                                         1.0
     Lys Arg Pro Leu Pro
                  20
     <210> 3
     <211> 13
     <212> PRT
     <213> Artificial Sequence
     <220>
     <223> Description of Artificial Sequence: vMIP-II
           derived peptide
     <400> 3
     His Arg Pro Asp Lys Cys Cys Leu Gly Tyr Gln Lys Arg
5
                                         10
     <210> 4
     <211> 10
    <212> PRT
     <213> Artificial Sequence
   <223> Description of Artificial Sequence: vMIP-II
          derived peptide
     <400> 4
     Leu Gly Ala Ser Trp His Arg Pro Asp Lys
     <210> 5
     <211> 22
     <212> PRT
     <213> Artificial Sequence
     <220>
      <223> Description of Artificial Sequence: vMIP-II
           derived peptide
      <400> 5
      Leu Gly Tyr Gln Lys Arg Pro Leu Pro Gln Val Leu Leu Ser Ser Trp
       1
                       5
                                         10
```

Tyr Pro Thr Ser Gln Leu 20

```
<210> 6
  <211> 20
  <212> PRT
  <213> Artificial Sequence
  <220>
  <223> Description of Artificial Sequence: vMIP-II
        derived peptide
  <400> 6
  Lys Pro Val Ser His Arg Pro Asp Lys Cys Cys Leu Gly Tyr Gln Lys
                                       1.0
  Arg Pro Leu Pro
               20
  <210> 7
  <211> 23
 <212> PRT
 <213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: vMIP-II
        derived peptide
  <400> 7
  Gln Val Leu Leu Ser Ser Trp Tyr Pro Thr Ser Gln Leu Cys Ser Lys
   1
                                                           15
  Pro Gly Val Ile Phe Leu Thr
               20
  <210> 8
  <211> 22
  <212> PRT
  <213> Artificial Sequence
  <220>
  <223> Description of Artificial Sequence: vMIP-II
        derived peptide
  <400> 8
```

```
Ser Lys Pro Gly Val Ile Phe Leu Thr Lys Arg Gly Arg Gln Val Cys
                                     10
 Ala Asp Lys Ser Lys Asp
             20
 <210> 9
 <211> 20
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: vMIP-II
       derived peptide
 <400> 9
 Ala Asp Lys Ser Lys Asp Trp Val Lys Lys Leu Met Gln Gln Leu Pro
                                    10
 Val Thr Ala Arg
<210> 10
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: vMIP-II
       derived peptide
 <400> 10
 Cys Thr Ser Gln Leu Ala Ser Lys Pro Gly Cys
  1 . 5
 <210> 11
 <211> 11
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: vMIP-II
       derived peptide
 <400> 11
```

```
Cys Phe Leu Thr Lys Arg Gly Arg Gln Val Cys
  1
                  5
<210> 12
<211> 21
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: vMIP-II
      derived peptide
<400> 12
Leu Gly Ala Ser Trp His Arg Pro Asp Lys Ala Ala Leu Gly Tyr Gln
                  5
                                     1.0
Lys Arg Pro Leu Pro
             20
<210> 13
<211> 21
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: vMIP-II
      derived peptide
<400> 13
Ala Gly Ala Ser Trp His Arg Pro Asp Lys Cys Cys Leu Gly Tyr Gln
                   5
                                                          15
                                     10
Lys Arg Pro Leu Pro
             20
<210> 14
<211> 21
 <212> PRT
 <213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: vMIP-II
      derived peptide
<400> 14
```

```
Leu Gly Ala Ser Ala His Arg Pro Asp Lys Cys Cys Leu Gly Tyr Gln
                   5
                                      10
 Lys Arg Pro Leu Pro
              20
 <210> 15
 <211> 21
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: vMIP-II
       derived peptide
 <400> 15
 Leu Gly Ala Ser Trp His Ala Pro Asp Lys Cys Cys Leu Gly Tyr Gln
                   5
                                      10
 Lys Arg Pro Leu Pro
              20
 <210> 16
 <211> 21
<212> PRT
<213> Artificial Sequence
<220>
 <223> Description of Artificial Sequence: vMIP-II
       derived peptide
 <400> 16
 Leu Gly Ala Ser Trp His Arg Pro Asp Ala Cys Cys Leu Gly Tyr Gln
  1
                    5
                                      10
  Lys Arg Pro Leu Pro
               20
  <210> 17
  <211> 21
  <212> PRT
  <213> Artificial Sequence
  <220>
  <223> Description of Artificial Sequence: vMIP-II
```

derived peptide

```
<400> 17
 Leu Gly Ala Ser Trp His Arg Pro Asp Lys Ala Cys Leu Gly Tyr Gln
                  5
                                      10
Lys Arg Pro Leu Pro
             20
<210> 18
<211> 21
<212> PRT
<213> Artificial Sequence
<220>
 <223> Description of Artificial Sequence: vMIP-II
      derived peptide
<400> 18
Leu Gly Ala Ser Trp His Arg Pro Asp Lys Cys Cys Leu Gly Tyr Ala
                                      10
Lys Arg Pro Leu Pro
             20
<210> 19
<211> 21
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: vMIP-II
      derived peptide
<400> 19
Leu Gly Ala Ser Trp His Arg Pro Asp Lys Cys Cys Leu Gly Tyr Gln
  1
                   5
                                     10
Lys Ala Pro Leu Pro
              20
<210> 20
<211> 21
<212> PRT
<213> Artificial Sequence
```

```
<220>
 <223> Description of Artificial Sequence: vMIP-II
       derived peptide
 <400> 20
 Pro Leu Pro Arg Lys Gln Tyr Gly Leu Cys Cys Lys Asp Pro Arg His
                                      10
 Trp Ser Ala Gly Leu
              20
 <210> 21
 <211> 21
 <212> PRT
 <213> Artificial Sequence
 <220>
 <221> VARIANT
 <222> (1)..(21)
 <223> all amino acids in this peptide fragement are
       D-amino acids
 <220>
<223> Description of Artificial Sequence: vMIP-II
       derived peptide
 Leu Gly Ala Ser Trp His Arg Pro Asp Lys Cys Cys Leu Gly Tyr Gln
   1
                                      10
                                                           15
Lys Arg Pro Leu Pro
              20
 <210> 22
 <211> 21
 <212> PRT
 <213> Artificial Sequence
 <220>
 <221> VARIANT
 <222> (1)..(21)
 <223> all amino acids in this peptide are D-amino acids
 <223> Description of Artificial Sequence: vMIP-II
```

```
<400> 22
Pro Leu Pro Arg Lys Gln Tyr Gly Leu Cys Cys Lys Asp Pro Arg His
                  5
                                     10
Trp Ser Ala Gly Leu
             20
<210> 23
<211> 21
<212> PRT
<213> Artificial Sequence
<220>
<221> VARIANT
<222> (1)..(10)
<223> amino acids residues #1 through #10 are D-amino
      acids, the remaining residues are L-amino acids
<220>
<223> Description of Artificial Sequence: vMIP-II
      derived peptide
Leu Gly Ala Ser Trp His Arg Pro Asp Lys Cys Cys Leu Gly Tyr Gln
  1
                  5
                                                          15
                                     10
Lys Arg Pro Leu Pro
             20
<210> 24
<211> 21
<212> PRT
<213> Artificial Sequence
<220>
<221> UNSURE
<222> (11)..(21)
<223> amino acids #11 through #21 are D-amino acids,
      #1-10 are L-amino acids
<220>
<223> Description of Artificial Sequence: vMIP-II
```

derived peptide

```
<400> 24
 Leu Gly Ala Ser Trp His Arg Pro Asp Lys Cys Cys Leu Gly Tyr Gln
                   5
                                      1.0
 Lys Arg Pro Leu Pro
              20
 <210> 25
 <211> 21
 <212> PRT
 <213> Artificial Sequence
 <220>
 <221> VARIANT
 <222> (1)..(21)
 <223> all amino acids are D-amino acids
<220>
 <223> Description of Artificial Sequence: vMIP-II
      derived peptide
 <400> 25
 Ala Gly Ala Ser Trp His Arg Pro Asp Lys Cys Cys Leu Gly Tyr Gln
                   5
                                     10
Lys Arg Pro Leu Pro
              20
<210> 26
 <211> 21
 <212> PRT
 <213> Artificial Sequence
 <220>
 <221> VARIANT
 <222> (1)..(21)
 <223> all amino acids are D-amino acids
 <220>
 <223> Description of Artificial Sequence: vMIP-II
       derived peptide
 <400> 26
 Leu Gly Ala Ser Ala His Arg Pro Asp Lys Cys Cys Leu Gly Tyr Gln
  1
                                      1.0
                                                          15
```

Lys Arg Pro Leu Pro 20

```
<210> 27
 <211> 21
 <212> PRT
 <213> Artificial Sequence
 <220>
 <221> VARIANT
 <222> (1)..(21)
 <223> all amino acids are D-amino acids
 <220>
 <223> Description of Artificial Sequence: vMIP-II
       derived peptide
 <400> 27
 Leu Gly Ala Ser Trp His Ala Pro Asp Lys Cys Cys Leu Gly Tyr Gln
  1
Lys Arg Pro Leu Pro
              20
<210> 28
<211> 21
 <212> PRT
 <213> Artificial Sequence
 <220>
 <221> VARIANT
 <222> (1)..(21)
 <223> all amino acids are D-amino acids
 <220>
 <223> Description of Artificial Sequence: vMIP-II
       derived peptide
 <400> 28
 Leu Gly Ala Ser Trp His Arg Pro Asp Ala Cys Cys Leu Gly Tyr Gln
   1
                   5
                                      10
                                                          15
 Lys Arg Pro Leu Pro
```

20

```
<210> 29
<211> 21
<212> PRT
<213> Artificial Sequence
<220>
<221> VARIANT
<222> (1)..(21)
<223> all amino acids are D-amino acids
<220>
<223> Description of Artificial Sequence: vMIP-II
      derived peptide
<400> 29
Leu Gly Ala Ser Trp His Arg Pro Asp Lys Ala Cys Leu Gly Tyr Gln
                                      10
Lys Arg Pro Leu Pro
            20
<210> 30
<211> 21
<212> PRT
<213> Artificial Sequence
<220>
<221> VARIANT
<222> (1)..(21)
<223> all amino acids are D-amino acids
<220>
<223> Description of Artificial Sequence: vMIP-II
      derived peptide
Leu Gly Ala Ser Trp His Arg Pro Asp Lys Cys Cys Leu Gly Tyr Ala
  1
                  5
                                     10
                                                          15
Lys Arg Pro Leu Pro
             20
<210> 31
<211> 21
<212> PRT
<213> Artificial Sequence
```

```
<220>
  <221> VARIANT
  <222> (1)..(21)
  <223> all amino acids are D-amino acids
 <220>
  <223> Description of Artificial Sequence: vMIP-II
        derived peptide
 <400> 31
  Leu Gly Ala Ser Trp His Arg Pro Asp Lys Cys Cys Leu Gly Tyr Gln
                    5
                                      10
  Lys Ala Pro Leu Pro
               20
 <210> 32
 <211> 21
 <212> PRT
 <213> Artificial Sequence
<220>
<221> VARIANT
 <222> (1)..(21)
<223> all amino acids are D-amino acids
<220>
 <223> Description of Artificial Sequence: vMIP-II
       derived peptide
  <400> 32
  Leu Gly Ala Ser Trp His Arg Pro Asp Lys Ala Ala Leu Gly Tyr Gln
                                      10
  Lys Arg Pro Leu Pro
              20
 <210> 33
  <211> 10
  <212> PRT
 <213> Artificial Sequence
 <220>
  <221> VARIANT
  <222> (1)..(10)
```